Get the Stockscreener App
3.90
1.02%
-0.04
After Hours:
3.96
0.06
+1.54%
Rezolute Inc stock is traded at $3.90, with a volume of 2.05M.
It is down -1.02% in the last 24 hours and down -22.16% over the past month.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
See More
Previous Close:
$3.94
Open:
$3.99
24h Volume:
2.05M
Relative Volume:
1.28
Market Cap:
$377.22M
Revenue:
-
Net Income/Loss:
$-81.49M
P/E Ratio:
-4.8208
EPS:
-0.809
Net Cash Flow:
$-73.48M
1W Performance:
+1.56%
1M Performance:
-22.16%
6M Performance:
+22.64%
1Y Performance:
-55.53%
1-Day Range:
$3.8714
$4.05
1-Week Range:
$3.73
$4.13
52-Week Range:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.90 | 377.22M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-11-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-11-25 | Downgrade | Craig Hallum | Buy → Hold |
| Dec-11-25 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
Rezolute Inc (NASDAQ: RZLT) Share Price, RZLT Stock News, RZLT Share Price & Updates - kalkine.ca
Rezolute, Inc. (RZLT) Stock Price, News, Quote & History - Yahoo! Finance Canada
RZLT Maintained by HC Wainwright & Co. -- Price Target Raised to $10 - GuruFocus
Rezolute (NASDAQ:RZLT) Given New $10.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. maintains Buy rating on Rezolute, $10 price target - TradingView
Citizens reiterates Rezolute stock rating on tumor trial results due By Investing.com - Investing.com Canada
Citizens reiterates Rezolute stock rating on tumor trial results due - Investing.com
Rezolute highlights ENDO data on congenital HI outcomes and tumor HI case series - scanx.trade
Rezolute Inc (RZLT) Faces Valuation Challenges Amid Cash Burn an - GuruFocus
Rezolute Q4FY26 Results: EPS misses estimate at $(0.20), net loss narrows - scanx.trade
Rezolute, Inc. FY 2026: Revenue $0 Net loss $77.6M, EPS $(0.75) — 10-K Summary - TradingView
Rezolute Fiscal Q4 Loss Narrows - marketscreener.com
Rezolute reports FY2026 net loss $77.6M, cash and investments $107.8M as of June 30, 2026 - TradingView
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - The Manila Times
Rezolute Reports $20.5 Million Fourth-Quarter Loss and $107.8 Million Cash - Quiver Quantitative
Rezolute Q4 net loss narrows as R&D expenses fall - TradingView
Press Release: Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update - Moomoo
Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Should I Buy RZLT? RZLT 2026 AnalysisIntellectia AI™ - intellectia.ai
Rezolute Inc. (RZLT) Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest BeatOne-Time Loss Impact - careplusvn.com
Rezolute Inc. (NV) (RZLT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Weekly Recap: Strong retention in sunRIZE extension and buy‑tilt at $6 - TradingView
Rezolute, Inc. expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Rezolute: Initiating At Sell Despite Attempts To Rescue Ersodetug Following sunRIZE Upset - Seeking Alpha
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Rezolute (RZLT) FDA Review Highlights Uncertain Path Amid Cash-F - GuruFocus
Rezolute says late-stage trial data for lead asset remains under FDA review - TradingView
Rezolute awaits FDA feedback on congenital HI treatment data By Investing.com - Investing.com Nigeria
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint - Yahoo Finance
Rezolute (RZLT) Updates FDA Review of Phase 3 Data Amid Unprofitable Status - GuruFocus
Rezolute awaits FDA feedback on congenital HI treatment data - investing.com
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism - The Manila Times
RZLT Q4'26 Earnings: EPS estimate is (0.15) USD - TradingView
FDA is still reviewing Rezolute’s experimental drug. No timeline is set. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Rezolute Stock Price Forecast. Should You Buy RZLT? - StockInvest.us
Rezolute (RZLT) CCO sells stock to cover RSU taxes - stocktitan.net
RZLT Q4'26 Earnings: revenue estimate is 0 USD - tradingview.com
Rezolute (RZLT) Shares Decline 7% as Stock Approaches Key Support at $4.39Diagonal Spread Trade - vinanet.vn
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Rezolute, Inc.'s (NASDAQ:RZLT) Shift From Loss To Profit - simplywall.st
Balyasny Asset Management L.P. Reduces Stake in Rezolute Inc (RZ - GuruFocus
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Rezolute Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT - MarketBeat
Balyasny reports 4.84% Rezolute (RZLT) stake in Schedule 13G/A - Stock Titan
Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Bank of America Corp (RZLT) discloses 1.2% Rezolute ownership in 13G/A - Stock Titan
Rezolute, Inc. (RZLT) gains 5.9% reported stake from Dellora Investments - Stock Titan
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rezolute Inc (RZLT) Stock News Today - TradingKey
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):